Genprex
Presence
Genprex is a company listed under the stock ticker GNPX (US).
Executives
View the org chart displaying its 21 main executives
Most searched biographies at Genprex
- Rodney Varner, Chairman of the Board and Chief Executive Officer
- Brent Longnecker, Director
- Jose Moreno, Director
Popular executive movements at Genprex
- Suzanne Thornton-Jones has joined the company as Senior Vice President, Regulatory Affairs (posted on August 23 2023).
Create your alert
to follow the executive moves at Genprex.
Biotechnology
Genprex has 2,287 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Delphia Therapeutics has just announced a $67 Million fundraising (posted on May 7 2024).
- Karius has just announced a $100 Million fundraising (posted on May 3 2024).
- Transcarent has just announced a $126 Million fundraising (posted on May 2 2024).
Popular contacts in Biotechnology
News
Press releases by Genprex
- Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System - Genprex
- April 2024 - Genprex
- Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer - Genprex
- Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting - Genprex
- Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Genprex
- Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Genprex
- Press Releases Archives - Page 20 of 20 - Genprex
- Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers - Genprex
- Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting - Genprex
- March 2024 - Genprex
- View more press releases Close
Social media about Genprex
- Genprex on Wikipedia, Google News & Yahoo Finance
- Genprex on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Rodney Varner 
